155 related articles for article (PubMed ID: 25828068)
1. Longitudinal study of acute haematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Zhu H; Zakeri K; Vaida F; Carmona R; Dadachanji KK; Bair R; Aydogan B; Hasan Y; Yashar CM; Mell LK
J Med Imaging Radiat Oncol; 2015 Jun; 59(3):386-93; quiz 394. PubMed ID: 25828068
[TBL] [Abstract][Full Text] [Related]
2. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy.
Mell LK; Schomas DA; Salama JK; Devisetty K; Aydogan B; Miller RC; Jani AB; Kindler HL; Mundt AJ; Roeske JC; Chmura SJ
Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1431-7. PubMed ID: 17996390
[TBL] [Abstract][Full Text] [Related]
3. The impact of bone marrow irradiation dose on acute haematologic toxicity in cervical cancer patients treated with concurrent chemoradiotherapy.
Chen M; Wang D; Bao Z; Yi Z; Mei Z; Sun S; Xiang Q; Yang C; Yang H; Qiu H; Xie C
Radiat Oncol; 2023 Apr; 18(1):66. PubMed ID: 37031167
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy.
Mell LK; Kochanski JD; Roeske JC; Haslam JJ; Mehta N; Yamada SD; Hurteau JA; Collins YC; Lengyel E; Mundt AJ
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1356-65. PubMed ID: 16757127
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 2 contouring methods of bone marrow on CT and correlation with hematological toxicities in non-bone marrow-sparing pelvic intensity-modulated radiotherapy with concurrent cisplatin for cervical cancer.
Mahantshetty U; Krishnatry R; Chaudhari S; Kanaujia A; Engineer R; Chopra S; Shrivastava S
Int J Gynecol Cancer; 2012 Oct; 22(8):1427-34. PubMed ID: 22932264
[TBL] [Abstract][Full Text] [Related]
6. Normal tissue complication probability modeling of acute hematologic toxicity in patients treated with intensity-modulated radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Luxton G; Mok EC; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):700-6. PubMed ID: 22414279
[TBL] [Abstract][Full Text] [Related]
7. Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.
Robinson M; Sabbagh A; Muirhead R; Durrant L; Van den Heuvel F; Hawkins M
Radiother Oncol; 2015 Nov; 117(2):246-51. PubMed ID: 26409831
[TBL] [Abstract][Full Text] [Related]
8. Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?
Wan J; Liu K; Li K; Li G; Zhang Z
Radiat Oncol; 2015 Aug; 10():162. PubMed ID: 26238572
[TBL] [Abstract][Full Text] [Related]
9. Correlation between radiation dose to ¹⁸F-FDG-PET defined active bone marrow subregions and acute hematologic toxicity in cervical cancer patients treated with chemoradiotherapy.
Rose BS; Liang Y; Lau SK; Jensen LG; Yashar CM; Hoh CK; Mell LK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1185-91. PubMed ID: 22270171
[TBL] [Abstract][Full Text] [Related]
10. Dosimetric predictors of acute hematologic toxicity during concurrent intensity-modulated radiotherapy and chemotherapy for anal cancer.
Franco P; Ragona R; Arcadipane F; Mistrangelo M; Cassoni P; Rondi N; Morino M; Racca P; Ricardi U
Clin Transl Oncol; 2017 Jan; 19(1):67-75. PubMed ID: 27037814
[TBL] [Abstract][Full Text] [Related]
11. Lumbosacral spine and marrow cavity modeling of acute hematologic toxicity in patients treated with intensity modulated radiation therapy for squamous cell carcinoma of the anal canal.
Cheng JC; Bazan JG; Wu JK; Koong AC; Chang DT
Pract Radiat Oncol; 2014; 4(3):198-206. PubMed ID: 24766688
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric parameters and absolute monocyte count can predict the prognosis of acute hematologic toxicity in cervical cancer patients undergoing concurrent chemotherapy and volumetric-modulated arc therapy.
Xiang X; Ding Z; Zeng Q; Feng L; Qiu C; Chen D; Lu J; Li N
Radiat Oncol; 2022 Mar; 17(1):48. PubMed ID: 35248087
[TBL] [Abstract][Full Text] [Related]
13. Clinical and dosimetric predictors of acute hematologic toxicity in rectal cancer patients undergoing chemoradiotherapy.
Yang TJ; Oh JH; Apte A; Son CH; Deasy JO; Goodman KA
Radiother Oncol; 2014 Oct; 113(1):29-34. PubMed ID: 25304718
[TBL] [Abstract][Full Text] [Related]
14. Pelvic bone marrow sparing intensity modulated radiotherapy reduces the incidence of the hematologic toxicity of patients with cervical cancer receiving concurrent chemoradiotherapy: a single-center prospective randomized controlled trial.
Huang J; Gu F; Ji T; Zhao J; Li G
Radiat Oncol; 2020 Jul; 15(1):180. PubMed ID: 32727497
[TBL] [Abstract][Full Text] [Related]
15. Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation.
Wang D; Yin Y; Zhou Q; Li Z; Ma X; Yin Y; Li B; Bai T; Li D; Zhu J
Med Phys; 2022 Jan; 49(1):756-767. PubMed ID: 34800297
[TBL] [Abstract][Full Text] [Related]
16. [(18)F]FDG-PET standard uptake value as a metabolic predictor of bone marrow response to radiation: impact on acute and late hematological toxicity in cervical cancer patients treated with chemoradiation therapy.
Elicin O; Callaway S; Prior JO; Bourhis J; Ozsahin M; Herrera FG
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1099-107. PubMed ID: 25442041
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer.
Mell LK; Tiryaki H; Ahn KH; Mundt AJ; Roeske JC; Aydogan B
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1504-10. PubMed ID: 18640499
[TBL] [Abstract][Full Text] [Related]
18. The absolute volume of PET-defined, active bone marrow spared predicts for high grade hematologic toxicity in cervical cancer patients undergoing chemoradiation.
Zhou YM; Freese C; Meier T; Go D; Khullar K; Sudhoff M; Lamba M; Kharofa J
Clin Transl Oncol; 2018 Jun; 20(6):713-718. PubMed ID: 29076030
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy.
Vitzthum LK; Heide ES; Park H; Williamson CW; Sheridan P; Huynh-Le MP; Sirak I; Wei L; Tarnawski R; Mahantshetty U; Nguyen C; Mayadev J; Yashar CM; Sacco AG; Mell LK
Front Oncol; 2020; 10():1179. PubMed ID: 32793487
[No Abstract] [Full Text] [Related]
20. Correlation between changes of pelvic bone marrow fat content and hematological toxicity in concurrent chemoradiotherapy for cervical cancer.
Wang C; Qin X; Gong G; Wang L; Su Y; Yin Y
Radiat Oncol; 2022 Apr; 17(1):70. PubMed ID: 35392934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
